🇺🇸

US SEC Filing Intelligence

· daily

Dow Jones 30 Stocks SEC Filings — March 30, 2026

Across the 50 filings in the USA Dow Jones 30 intelligence stream (primarily small/mid-cap proxies but including DJ30 names like Boeing and Baker Hughes), sentiment is mixed with 14 positive, 18 mixed, and 12 neutral/negative, reflecting resilient capital raises and M&A amid revenue volatility. Period-over-period trends show revenue growth in 8/22 reporting companies (avg +72% YoY where positive, e.g., CBAK Q4 +131.8%, Global Arena Q1 +72%), but declines in 14 (avg -15%, e.g., Soluna FY2025 -22%, ARKO -12.3%), with gross margins compressing broadly (avg -300bps in mixed reporters like CBAK 23.7% to 9.4%). Biotech firms dominate positive catalysts, narrowing net losses (avg -25%, e.g., Unicycive -28%, Reviva -33%) ahead of FDA milestones, while SPACs advance mergers (Vine Hill 92.6% approval). Capital allocation leans toward equity/debt raises ($142M Soluna, $112.5M Capstone) over dividends/buybacks (none noted), signaling growth focus but dilution risks. M&A completions (Leidos $2.4B, CVD SDC $16.9M) and credit amendments (Ingevity $750M revolver) highlight deal momentum, with DJ30 filings mostly neutral proxy boilerplate. Portfolio implication: Opportunistic buys in biotech/SPAC catalysts, caution on revenue-dependent industrials amid margin pressure.

37 high priority 13 medium 50 total filings
· daily

US SEC Filings Daily Market Digest — March 30, 2026

Across 50 SEC filings for March 30, 2026, 10-Ks reveal polarized financial trends with 12/22 reporting revenue growth (avg +85% YoY in winners like General Enterprise Ventures +195%, Embraer +18.5%) but 15 showing widening net losses (avg +150% YoY, e.g., Picard Medical +28%, Origin Materials +198%) amid impairments and high expenses; SPACs (9 filings) universally report no revenue, mounting deficits (avg -$500K), and going concern doubts. Biotech/pharma shines with Alumis' Phase 3 psoriasis trial success and OnKure's $150M raise for PI3K inhibitors, contrasting Dyadic's Nasdaq equity deficiency. Capital allocation favors buybacks (News Corp $1B program, ConocoPhillips $5B in 2025) and financings ($119M Soluna cash surge), while M&A/strategic deals (RYVYL $10M deposit acquisition, Contango exchangeables) signal consolidation. Energy (Conoco, Endeavour) shows resilience with production gains and audit stability, but REITs/CRE (Presidio, CIM) face NOI pressures yet NAV stability. Forward catalysts cluster in H2 2026 (NDAs, pilots) with May 12 AGMs for Conoco/Accelerant; overall, selective bullish signals in biotech/energy amid broad microcap risks, favoring nimble portfolios.

38 high priority 12 medium 50 total filings
· daily

S&P 500 Consumer Discretionary Sector SEC Filings — March 30, 2026

Across 50 SEC filings from the S&P 500 Consumer Discretionary stream (broadly including retail, entertainment, and adjacent sectors), sentiment is predominantly mixed (14/50), with positive operational milestones (e.g., Sable Offshore oil resumption, Fermi $1.8B raised) offset by financial pressures like revenue declines (Helio -65% YoY), margin compressions (banks avg NIM down ~40bps), and impairments (Falcon's $8.3M). Key period-over-period trends show revenue growth in 12 firms averaging +45% YoY (outliers: Fathom +25%, Falcon's +121%), but net losses persisted or widened in 18 cases; gross margins expanded in retail (Lulus +640bps Q4) while compressing in finance/REITs (avg -150bps). Capital allocation favors dividends/special payouts (Sanfilippo $1.50, Blue Ridge $0.60, Brookfield $0.0721) over buybacks, with M&A/divestitures prominent ($142.8M Affinity merger, $292.5M Compass sale). Portfolio-level patterns indicate turnaround potential in retail/entertainment amid consumer softness, but risks from NPAs rising 200%+ in banks and ongoing deficits (Pacific Coast). Critical implications: near-term catalysts from Q2'26 AGMs/mergers offer arb plays; monitor deleveraging post-asset sales for alpha.

25 high priority 25 medium 50 total filings
· daily

S&P 500 Healthcare Sector SEC Filings — March 30, 2026

Across 48 SEC filings from the USA S&P 500 Healthcare stream (primarily biotech, pharma, med devices amid broader financials), dominant themes include robust M&A activity (BSX-Penumbra merger, Aurinia-Kezar acquisition) and FDA catalysts (Unicycive OLC PDUFA June 29, 2026), with mixed FY2025 financials showing 6/10 biotechs narrowing net losses YoY (avg -25%, e.g., Unicycive -28% to $26.6M) but rising G&A/R&D expenses averaging +40%. Period-over-period trends reveal healthcare innovators extending cash runways into 2027 (Unicycive $54.9M, Aura $144.2M) despite no revenues, contrasting with deteriorations like Ensysce net loss widening 28% to $10.2M and Interpace PancraGEN discontinuation post-CMS loss. Capital allocation leans toward equity raises (Artelo $11M private placement) and buybacks (News Corp $1B program), while non-healthcare filings (e.g., CIM REIT portfolio -1.6% YoY) dilute focus but highlight relative biotech resilience. Critical developments like Sight Sciences $34M patent win and ProCap merger approval signal upside, but risks from delistings (Interpace, Zivo) and going concerns (CISO) warrant caution. Portfolio-level, healthcare shows +9% avg revenue growth in reporting firms (CareView +9%) with margin stabilization, positioning for H2 2026 catalysts amid sector M&A premiums.

29 high priority 19 medium 48 total filings
· daily

US Executive Compensation Proxy SEC Filings — March 30, 2026

Across 34 DEF 14A proxy statements filed around March 30, 2026, a dominant theme is robust 2025 performance with 12 companies reporting double-digit revenue growth (avg 10% YoY, e.g., Frontdoor +14%, KBR +11%) and 8 highlighting EBITDA expansions (avg +12% YoY), contrasted by mixed signals from leadership transitions in 7 firms and disruptions like merger terminations. Capital allocation trends show aggressive shareholder returns with $3B+ debt paydown (Sun Communities), $5B buybacks (ConocoPhillips), and dividend hikes in 6 companies (avg +12%, e.g., Patrick +17.5%), signaling financial health amid governance focus via high Say-on-Pay support (avg 96% where reported). Biotech/pharma firms (Tonix, Onconetix, Auddia, Atossa, XOMA) cluster reverse stock split proposals, indicating compliance risks, while energy/industrials (Conoco, KBR, Xylem) lead positive sentiment (9/10 positive filings). Portfolio-level, margins expanded in 6/10 with operational metrics (e.g., Conoco 15% drilling efficiency gain), but CEO changes (Rayonier, Fortune Brands, Pitney Bowes) and SPAC extensions (GP-Act III) flag caution. May 2026 annual meetings form a dense catalyst calendar (25+ events), with declassification votes and comp approvals as key votes. Implications favor cyclicals with buybacks over speculative biotechs.

34 high priority 34 total filings
· daily

US IPO Pipeline SEC S-1 Filings — March 30, 2026

The IPO Pipeline stream features two SEC filings on March 30, 2026: Cadre Holdings' S-4 shelf registration for up to 7,500,000 shares to fund future acquisitions and Elmet Group Co.'s S-1 for its initial public offering on Nasdaq under 'ELMT'. No period-over-period financial comparisons are available, as Elmet's preliminary prospectus explicitly provides no financial performance data and Cadre's filing focuses on share registration without operational metrics. Neutral sentiment prevails across both, with Elmet carrying higher materiality (10/10) due to its IPO status as an emerging growth and smaller reporting company in fabricated metal products. Cadre signals proactive M&A strategy in safety equipment markets, while Elmet highlights speculative high-risk entry into public markets post-reorganization on January 2, 2026. Portfolio-level pattern: Early-stage capital market preparations amid neutral outlook, with no YoY/QoQ trends but potential for new listings and dilution. Market implications include monitoring for IPO catalysts and acquisition targets, positioning investors for alpha in industrials.

2 high priority 2 total filings
· daily

Global High-Priority Regulatory Events — March 30, 2026

Across 50 filings from March 30, 2026, focused on global high-priority events, dominant themes include SPAC mergers advancing toward imminent closings, heavy promoter encumbrances and pledge releases in Indian firms signaling liquidity pressures, mixed 10-K results with revenue surges (e.g., OneMedNet +111% YoY) offset by widening losses and impairments (e.g., Origin Materials -40% revenue, $196M impairment), and biotech financings amid going concern warnings. Period-over-period trends reveal 8/15 10-K filers with revenue growth averaging +85% YoY but losses expanding in 10/15 (avg +150%), driven by expense spikes and asset write-downs, while capital raises ($150M OnKure, $750M Ingevity revolver) bolster balance sheets. Critical developments like Vine Hill's 92.6% merger approval (closing Mar 31), IL&FS bond default, and IndusInd SFIO probe heighten volatility risks. Portfolio-level patterns show crypto/AI names with asset growth but volatility (AIxCrypto assets +568% YoY), shipping/energy facing covenant pressures, and Indian banks/pharma with encumbrance fluctuations (e.g., IndusInd promoters to 0% encumbered). Implications favor short-term trading around catalysts like Mar 31 closings and May AGMs, with caution on insolvencies and Nasdaq deficiencies.

50 high priority 50 total filings
· daily

US Earnings Financial Results SEC Filings — March 30, 2026

Across 50 10-K and 10-Q filings from March 30, 2026, primarily small-cap biotechs, SPACs, crypto/AI firms, and financial trusts, sentiment is mixed (70% of filings), with 18 companies narrowing net losses YoY (avg improvement 40%, e.g., OneMedNet -72%, ImmuCell -52%) amid revenue volatility: 14 firms grew revenue (avg +95% YoY, outlier OneMedNet +111%), 13 declined (avg -18%, e.g., Soluna -22%, Origin -40%). Biotechs (12 filings) show R&D cuts in 6 but persistent cash burn (avg op cash use +15%), while SPACs (12) hold trust assets ($10B+ aggregate) but report deficits and no combinations. Crypto firms (5) post impairments ($40M+) offset by financing ($150M+ inflows). Capital allocation leans to financing raises ($1B+ aggregate) over dividends/buybacks; no insider trades noted, but 8 firms flag going concerns. Portfolio implications: Selective opportunities in turnarounds like Galaxy Gaming (profitability flip), risks in high-burn biotechs and pre-IPO SPACs; sector rotation toward profitable niches like banks (GBank NI +12%).

50 high priority 50 total filings
· daily

US SEC Trading Suspension Halt Orders — March 30, 2026

Across 7 US-listed companies facing trading suspensions or delisting risks in late March 2026, themes center on Nasdaq $1 minimum bid price violations (4/7 filings), financial metric deficiencies (2/7), and one voluntary delist post-SPAC merger, highlighting small-cap liquidity and compliance struggles. Positive resolutions emerged in Vine Hill Capital's 92.6% merger approval leading to relisting as Odysseus, Sky Quarry's post-reverse-split compliance regain, and Triller's conditional reinstatement path, contrasting with ongoing risks for Dyadic, Greenlane, InMed, and Skillsoft. No explicit YoY/QoQ financial trends available, but repeated non-compliance periods (e.g., Sky Quarry's two 180-day extensions expiring Sep 2025/Mar 2026) signal deteriorating bid prices over 12+ months. Mixed sentiment prevails (3 negative, 2 mixed, 1 positive, 1 negative on NYSE), with materiality high (8-10/10), implying imminent trading halts or delistings for non-compliant firms, pressuring valuations and liquidity. Portfolio-level pattern: reverse splits in 3/7 (Sky Quarry 1:8, Greenlane cumulative 1:8250) as desperate compliance tools, often failing long-term. Market implication: short-term volatility spikes around Mar 31 deadlines, potential OTC trading shifts reducing institutional access.

7 high priority 7 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — March 30, 2026

Across 50 filings in the USA Corporate Distress & Bankruptcy stream (Mar 30, 2026 period), proactive liquidity management dominates with 25+ credit amendments/extensions/increases (e.g., Nexstar $1.75B Term B-7, Ares $350M facility to $400M accordion) signaling lender support amid distress risks. True distress limited to 1 Chapter 11 (Twin Hospitality governance overhaul), 7 Nasdaq/NYSE deficiencies/delisting threats (Dyadic equity <$2.5M, Greenlane post-multiple reverses), and reverse splits (agilon 1:25, Safe & Green 1:20). Positive asset sales for cash (Spire $215M gas marketing, Star Equity $1.69M properties) and equity raises (OnKure $150M, Capstone $112.5M) outpace negatives. No broad YoY/QoQ declines reported, but Spire cut FY27 EPS guidance to $5.40-$5.60 from $5.65-$5.85 despite FY26 affirm. Sentiment: 20 positive, 15 neutral/mixed, 8 negative; portfolio trend shows contained distress via refinancing, but small-cap Nasdaq risks elevated. Implications: Favor companies completing financings (e.g., closings 3/31/26) over compliance-challenged names.

50 high priority 50 total filings
· daily

US Executive Officer Management Changes SEC — March 30, 2026

Across 35 SEC filings from March 26-30, 2026, focused on US executive and director changes, a high volume of leadership transitions signals potential strategic realignments amid economic pressures, with 15+ appointments, 12 resignations/retirements, and several interim roles in healthcare/biotech (12 filings), industrials, and tech sectors. Positive themes include experienced hires (e.g., Teladoc's Susan Salka with $5B revenue growth track record) and CEO sacrifices (Rocket Lab's Peter Beck forfeiting 392k RSUs and slashing salary to $1), contrasting risks from discord-driven exits (Ensysce director resignation over severance disputes) and sudden terminations (Newton Golf CEO). No broad YoY/QoQ financial declines noted, but reaffirmed guidance (Inogen Q1/FY2026), performance-tied incentives (UHS 150% CEO bonus target on adj. EPS/ROC), and salary hikes (Graham CEO to $600k, + undisclosed prior) indicate focus on growth incentives over cuts. Capital allocation leans toward equity incentives (RSUs/PBRSUs in 8 filings) vs buybacks/dividends. Portfolio implication: Healthcare shows churn (e.g., Tenet, Entergy transitions) but positive hires; small caps like biotechs exhibit instability (5 resignations), urging caution on execution risks while opportunities arise from undervalued turnarounds with strong interim leadership.

35 high priority 35 total filings
· daily

US Corporate Board Director Changes SEC Filings — March 30, 2026

Across 35 SEC filings on USA Board Room Changes dated March 30, 2026, there is elevated executive and board turnover with 18 resignations/departures (e.g., CEOs, CFOs, directors) and 22 appointments/promotions, signaling potential strategic shifts amid neutral-to-positive sentiment in 70% of cases. Healthcare/biotech dominates (12/35 filings) with experienced hires like Susan Salka at Teladoc and Bill Gassen at HealthEquity, while finance roles see frequent transitions (e.g., Entergy Texas, Tenet, Commerce Bancshares). No broad period-over-period financial declines noted, but Inogen reaffirmed Q1/FY2026 guidance post-CFO change, and SunPower secured strong shareholder approval (>66M votes) for equity expansions amid mixed sentiment. Key themes include internal promotions for continuity (e.g., Cross Country, Trustmark) and pay adjustments for capital preservation (Rocket Lab CEO salary to $1). Portfolio-level pattern: 8/12 healthcare filings bullish on growth expertise additions vs. isolated discord (Ensysce). Implications: Bullish for turnaround plays with proven hires, cautious on sudden C-suite exits signaling execution risks; monitor Q2 catalysts like retirements and annual meetings.

35 high priority 35 total filings
· daily

US Merger & Acquisition SEC Filings — March 30, 2026

The March 30, 2026, filings reveal heightened USA M&A and takeover activity, with 4 major acquisitions/divestitures (Leidos $2.4B, Addentax control stake, Bitmine blockchain assets, Aimco $455M property sale) signaling strategic expansion in energy infrastructure, fashion, crypto staking, and REIT portfolio optimization. SPACs dominate the rest, with extensions (Constellation to April 29), redemptions (ASPAC shares down 71% YoY post-Oct), resignations (UY Scuti CFO), and voting (Relativity), reflecting ongoing deal pursuits amid deadline pressures. Positive sentiment prevails in 4/8 filings (50%), mixed in Aimco due to pro forma revenue decline 33% to $92.6M for 2025 despite liquidity boost (cash +$547.5M, debt -to $457.3M). No insider trading or dividend changes noted across filings, but transaction terms highlight deferred payments/earnouts (Bitmine $14M deferred + $11.8M earnout). Portfolio trend: Acquirers gaining scale (Leidos doubling energy presence), SPACs managing liquidity for catalysts; watch SPAC merger votes for takeover upside.

8 high priority 8 total filings
· monthly

US Pre-Market SEC Filings Roundup — March 30, 2026

Across 50 overnight SEC filings, dominant themes include mixed financial results in 10-Ks with revenue growth in 6/15 reporting companies (avg +60% YoY outliers like General Enterprise Ventures +195%) offset by widening losses (e.g., Picard Medical net loss +28%, Origin Materials -198%) and impairments; SPACs (8 filings) universally show no revenue, cash burn, and going concern doubts. Biotech sector shines with positive trial data (Alumis Phase 3 success) and funding ($150M OnKure), while energy (ConocoPhillips +15% drilling efficiency) and aviation (Embraer +18.5% revenue) report strength amid margin pressures. Capital allocation leans toward buybacks (News Corp $1B program) and dividends (steady in Presidio, Cottonwood), but debt issuances/amendments (Amphenol, Nexstar $1.75B) signal leverage. Forward-looking catalysts cluster in H2 2026 (NDAs, pilots, data readouts), with M&A momentum (RYVYL, Volato). Portfolio-level: Margin compression avg -50bps in 7/10-Ks, cash surges via financing in 5 firms (Soluna +$68M), but Nasdaq deficiencies and going concerns flag 4 high-risk names. Implications: Tactical buys in biotech/energy catalysts, caution on microcaps/SPACs pre-market.

38 high priority 12 medium 50 total filings
· daily

New Federal Contractors — March 29, 2026

Five new federal contracts totaling $1.33B in obligations signal bullish momentum for health/tech and security providers, with HHS dominating at ~$699M (53% of total) via CMS software verification and NIH R&D. Long-term performance periods to 2027-2029 offer revenue stability, though options could unlock $6B+ upside across portfolios. Neutral stance on nonprofit Family Endeavors due to T&M pricing and shorter horizon, but overall portfolio supports overweight in gov-contracted health R&D and IT services.

5 total filings
· daily

Significant Contract Modifications ($10M+) — March 29, 2026

Five significant contract modifications totaling $1.33B in obligations highlight sustained federal demand in health services (52% HHS allocation via Carahsoft and Leidos), with four bullish signals driven by long-term commitments to 2027-2029 and massive option upside exceeding $5B combined. Neutral signal on nonprofit Family Endeavors reflects full $347M outlay but limited scalability. Investors should prioritize Leidos, Carahsoft for revenue visibility amid firm fixed price risks and low outlays in select contracts like Idemia.

5 total filings
· daily

Contract Deobligations Alert — March 29, 2026

Five contract deobligations totaling $1.33B highlight sustained U.S. government commitments to health/tech services (52% of value via HHS), facilities support, security, and investment management, with 4 bullish signals driven by high outlays ($1.1B already spent across records) and long-term horizons to 2029. Largest exposures favor Carahsoft ($465M HHS software) and Family Endeavors ($347M DOI facilities), signaling portfolio stability for institutional holders in defense/health contractors. Neutral Family Endeavors stands out as nonprofit with massive unexercised options ($3.3B potential), warranting scrutiny amid bullish peers.

5 total filings
· daily

Contract Option Exercises — March 29, 2026

Option exercises totaling $1.33B signal strong long-term U.S. government commitments through 2029, dominated by HHS ($699M across two contracts) in software publishing and biomed R&D, yielding 4 bullish signals for Leidos Holdings, Carahsoft, IDEMIA, and NISA. Neutral stance on nonprofit Family Endeavors due to T&M pricing and short horizon despite $3.3B options upside. Investors should prioritize public Leidos for predictable revenue, monitor $0 outlays on IDEMIA's $204M, and track HHS expansion risks/opportunities.

5 total filings
· daily

Federal IT & Cybersecurity Contracts — March 29, 2026

Carahsoft Technology Corp secured a $465M obligated delivery order from CMS (HHS) for income verification software, with $337M already outlayed and potential upside to $2.1B via options through 2028. This represents a major bullish signal for federal IT/software publishers amid healthcare admin digitization. Investors should monitor option exercises and outlays for revenue acceleration, tempered by firm-fixed-price margin risks.

1 total filings